| Study |
Benefits |
|
| EORTC (Bolla et al, 1997) |
77% decrease in cancer-specific death (P = 0.01) |
| RTOG trial (Pilepich et al,
1997) |
37% decrease for Gleason score 8-10 (P = 0.03) |
| Quebec Screening Trial (Labrie et al,
1999a) |
64% decrease in cancer-specific death (P = 0.0002) |
| (Messing et al, 1999) |
81% decrease (P = 0.001) |
| (Granfors et al, 1998) |
39% decrease in cancer-specific death (P = 0.06) |
| (Hanks et al, 2000) |
59% decrease for Gleason score 8-10 (P = 0.007) |
